Displaying all 13 publications

  1. Drakaki A, Habib M, Sweeney AT
    Am J Med, 2009 Dec;122(12):e5-6.
    PMID: 19958876 DOI: 10.1016/j.amjmed.2009.06.016
    Hypokalemic thyrotoxic periodic paralysis is a potentially life-threatening complication of hyperthyroidism, defined by 3 characteristic features: thyrotoxicosis, hypokalemia, and acute painless muscle weakness. In this case, a 25-year-old Malaysian man presented with acute, painless lower extremity weakness immediately after a meal. His associated symptoms included palpitations, tremor, and anxiety. He also reported a 30-pound unintentional weight loss over the previous 18 months, dyspnea on exertion, and insomnia.
  2. Lee SW, Liong ML, Yuen KH, Leong WS, Chee C, Cheah PY, et al.
    Am J Med, 2008 Jan;121(1):79.e1-7.
    PMID: 18187077 DOI: 10.1016/j.amjmed.2007.07.033
    Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) afflicts 2%-10% of adult men. Available therapies offer little or no proven benefit. Because acupuncture represents an attractive "natural" therapy, we compared the efficacy of acupuncture to sham acupuncture for CP/CPPS.
  3. Chaubal T, Bapat R
    Am J Med, 2018 09;131(9):e371-e372.
    PMID: 29730363 DOI: 10.1016/j.amjmed.2018.04.020
  4. Chaubal T, Bapat R
    Am J Med, 2017 Dec;130(12):e533-e534.
    PMID: 28716459 DOI: 10.1016/j.amjmed.2017.06.016
  5. Chaubal T, Bapat R
    Am J Med, 2017 Nov;130(11):e493-e494.
    PMID: 28602875 DOI: 10.1016/j.amjmed.2017.05.020
  6. Chaubal TV, Bapat R, Poonja K
    Am J Med, 2017 10;130(10):e451.
    PMID: 28528920 DOI: 10.1016/j.amjmed.2017.04.026
  7. Ravichandran J, Woon SY, Quek YS, Lim YC, Noor EM, Suresh K, et al.
    Am J Med, 2019 03;132(3):362-366.
    PMID: 30503877 DOI: 10.1016/j.amjmed.2018.11.017
    PURPOSE: The purpose of this study was to examine the association of circulating concentrations of high-sensitivity cardiac troponin I (hs-cTn) in the various trimesters of pregnancy in patients with and without hypertension.

    METHODS: This was a prospective cross-sectional study of pregnant and postnatal women aged between 18-35 years with no coexisting diseases. Serum samples were analysed for hs-TnI.

    RESULTS: A total of 880 women (mean age = 29.1 years [standard deviation = 5.1 years]) were recruited with 129 (14%), 207 (24%), and 416 (47%) patients in the first, second, and third trimesters, respectively. Ninety (10%) participants were recruited in the postnatal period. During pregnancy 28 (3%) patients were classified as having pregnancy-induced hypertension and 10 (1%) as preeclampsia. High-sensitivity cardiac troponin I was measurable in 546 (62%) participants with a median of 1 ng/L (range 0 to 783 ng/L). Troponin concentrations were above the 99th percentile in 19 (2%) individuals. Patients with pregnancy-induced hypertension and preeclampsia had higher concentrations of hs-TnI (median 11 ng/L [interquartile range (IQR) 6 to 22 ng/L] vs 12ng/L [IQR 3 to 98 ng/L] vs 1 ng/L [IQR 0 to 1 ng/L]). In logistic regression modeling hs-cTnI concentration remained an independent predictor of pregnancy-induced hypertension or preeclampsia in both unadjusted and adjusted models (odds ratio 9.3 [95% confidence interval 5.8 to 16.3] and 11.5 [95% confidence interval 6.3 to 24.1], respectively, per doubling of hs-TnI concentrations).

    CONCLUSIONS: Cardiac troponin measured using a high-sensitivity assay is quantifiable in the majority of young pregnant women with 2% of individuals having concentration above the 99th percentile sex-specific threshold. Patients with pregnancy-induced hypertension or preeclampsia had higher cardiac troponin concentrations. Cardiac troponin was a strong independent predictor of pregnancy-induced hypertension or preeclampsia in pregnant and postnatal women.

  8. Kanneppady SS, Kanneppady SK, Chaubal T, Bapat R, Pandurangappa R, Oo AM, et al.
    Am J Med, 2019 04;132(4):e538-e539.
    PMID: 30503886 DOI: 10.1016/j.amjmed.2018.11.019
  9. Chaubal TV, Bapat R
    Am J Med, 2021 04;134(4):e270.
    PMID: 32997980 DOI: 10.1016/j.amjmed.2020.08.031
  10. Wei SSK, Bapat R, Chaubal T
    Am J Med, 2019 10;132(10):e737.
    PMID: 31103649 DOI: 10.1016/j.amjmed.2019.04.039
  11. Goldhaber SZ, Ageno W, Casella IB, Chee KH, Schellong S, Singer DE, et al.
    Am J Med, 2020 08;133(8):936-945.
    PMID: 32325043 DOI: 10.1016/j.amjmed.2020.03.036
    BACKGROUND: The safety and efficacy of nonvitamin K antagonist oral anticoagulants (NOACs) for the treatment of venous thromboembolism (VTE) have been established in randomized controlled trials, but limited data are available on their use in clinical practice across geographical regions.

    METHODS: In the international RE-COVERY DVT/PE observational study (enrollment January 2016 to May 2017), we sought to characterize the patient population and describe the prescribed anticoagulant. Patient characteristics and anticoagulants administered after objective diagnosis of VTE were recorded at the baseline visit and again at hospital discharge or at 14 days after the diagnosis, whichever was later.

    RESULTS: A total of 6095 patients were included, 50.2% were male, and the mean age was 61.5 years. The most common comorbidities were hypertension (35%), diabetes mellitus (11%), cancer (11%), prior VTE(11%), and trauma/surgery (7%). Overall, 77% of patients received oral anticoagulants, with 54% on NOACs and 23% on vitamin K antagonists (VKAs); 20% received parenteral anticoagulation only. NOACs comprised about 60% of anticoagulant treatment in Europe and Asia but substantially less in Latin America (29%) and the Middle East (21%). For NOAC therapies, the distribution (as a percentage of the total cohort) was rivaroxaban 25.6%, dabigatran 15.5%, apixaban 11.3%, and edoxaban 1.7%. Treatment with NOACs was less frequent in patients who had cancer, chronic renal disease, heart failure, or stroke.

    CONCLUSIONS: These findings enhance our understanding of baseline characteristics and the initial management of patients with VTE in routine practice.

  12. Bhatia S, Kohli S, Selvadurai SS
    Am J Med, 2021 06;134(6):e390-e391.
    PMID: 33359776 DOI: 10.1016/j.amjmed.2020.11.016
  13. Chaubal DT, Bapat DR
    Am J Med, 2021 11;134(11):e552.
    PMID: 34273288 DOI: 10.1016/j.amjmed.2021.06.019
Related Terms
Contact Us

Please provide feedback to Administrator (tengcl@gmail.com)

External Links